Our study provides a feasible strategy by targeting ALDH2 for the treatment of obesity-associated metabolic disorders which are rising rapidly in human populations, particularly in the East and South Asia. Here, ALDH2 is linked to obesity due to melanocortin 4 receptor deficiency.